JPH04135566A - Composition for artificial crystalline lens and artificial crystalline lens - Google Patents
Composition for artificial crystalline lens and artificial crystalline lensInfo
- Publication number
- JPH04135566A JPH04135566A JP2258098A JP25809890A JPH04135566A JP H04135566 A JPH04135566 A JP H04135566A JP 2258098 A JP2258098 A JP 2258098A JP 25809890 A JP25809890 A JP 25809890A JP H04135566 A JPH04135566 A JP H04135566A
- Authority
- JP
- Japan
- Prior art keywords
- pmma
- crystalline lens
- pvdf
- artificial crystalline
- artificial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000695 crystalline len Anatomy 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims abstract description 22
- 239000004926 polymethyl methacrylate Substances 0.000 claims abstract description 22
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims abstract description 14
- 239000002033 PVDF binder Substances 0.000 claims abstract description 10
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract description 4
- 229920001519 homopolymer Polymers 0.000 abstract description 4
- 239000008188 pellet Substances 0.000 abstract description 3
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000004898 kneading Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 6
- 239000003999 initiator Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012662 bulk polymerization Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 2
- 238000009863 impact test Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 230000010069 protein adhesion Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010557 suspension polymerization reaction Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002945 Aphakia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
「産業上の利用分野］
本発明は、ポリメチルメタクリレート（ＰＭＭＡ）とポ
リビニリデンフルオライド（ＰＶｄＦ）の相溶体から成
る人工水晶体用組成物および該人工水晶体用組成物から
成る人工水晶体に関する。Detailed Description of the Invention "Industrial Application Field" The present invention provides a composition for an artificial lens comprising a compatible solution of polymethyl methacrylate (PMMA) and polyvinylidene fluoride (PVdF), and This article relates to an artificial crystalline lens.
［従来技術］ 従来、ＰＭＭＡが人工水晶体の素材として有用である。[Prior art] Conventionally, PMMA has been useful as a material for artificial crystalline lenses.
最近、光学部に加えて支持部もＰＭＭＡからできており
、光学部と支持部が一体となった１ピースレンズが主流
となりつつある。しかし、ＰＭＭＡの支持部は折れ易い
という欠点があった。Recently, in addition to the optical part, the supporting part is also made of PMMA, and one-piece lenses in which the optical part and the supporting part are integrated are becoming mainstream. However, the PMMA support part has the drawback of being easily broken.
この欠点を解決するためにＴｇの低いメチルメタクリレ
ート（ＭＭＡ）／エチルアクリレート（ＥＡ）共重合体
を用いることが考えられるが、ＥＡは安全性において問
題かないと言い切れない。In order to solve this drawback, it is possible to use a methyl methacrylate (MMA)/ethyl acrylate (EA) copolymer with a low Tg, but it cannot be said that EA does not have safety problems.
［発明が解決しようとする課題１
本発明の１つの目的は、安全性の確認されている素材か
ら成る人工水晶体を提供することにある。[Problem to be Solved by the Invention 1] One object of the present invention is to provide an artificial crystalline lens made of a material whose safety has been confirmed.
本発明の別の目的は、光学的特性を維持しつつ耐衝撃性
に優れた人工水晶体を提供することにある。Another object of the present invention is to provide an artificial crystalline lens that maintains its optical properties and has excellent impact resistance.
［課題を解決するための手段］
１つの要旨によれば、本発明は、ＰＭＭＡとＰＶｄＦの
相溶体から成る人工水晶体用組成物を提供する。[Means for Solving the Problems] According to one aspect, the present invention provides a composition for an artificial lens comprising a compatible solution of PMMA and PVdF.
他の要旨によれば、本発明は、前記人工水晶体用組成物
から成る人工水晶体を提供する。According to another aspect, the present invention provides an artificial lens comprising the composition for an artificial lens.
ＰＭＭＡは、メチルメタクリレートから成るホモポリマ
ーである。ＰＭＭＡの分子量はＩ Ｏ，０００〜１ｏｏ
ｏ、ｏｏｏである。ＰＭＭＡの製造は、塊状重合、溶液
重合、乳化重合および懸濁重合のいずれによっても行え
る。ＰＭＭＡの製造は、例えば、ガラスフラスコ中で、
けん化ポリビニルアルコールを溶解した水中でＭＭＡを
強く撹拌することにより分散させ、開始剤を添加して、
重合させることによって行える。開始剤は、例えば、過
酸化ベンゾイルである。重合は、例えば、７５℃の温度
で３時間で行える。ＰＭＭＡの量は、通常、組成物の２
０〜８０重量％、好ましくは４０〜６０重量％である。PMMA is a homopolymer composed of methyl methacrylate. The molecular weight of PMMA is IO,000~1oo
o, ooo. PMMA can be produced by any of bulk polymerization, solution polymerization, emulsion polymerization, and suspension polymerization. The production of PMMA can be carried out, for example, in a glass flask.
MMA is dispersed by strong stirring in water in which saponified polyvinyl alcohol is dissolved, an initiator is added,
This can be done by polymerization. The initiator is, for example, benzoyl peroxide. Polymerization can be carried out, for example, at a temperature of 75° C. for 3 hours. The amount of PMMA is typically 2% of the composition.
0 to 80% by weight, preferably 40 to 60% by weight.
ＰＶｄＰはビニリデンフルオライドのホモポリマーであ
る。ＰＶｄＦの分子量は１０，０００〜１ｏｏｏ、ｏｏ
ｏである。ＰＶｄＦの製造は、塊状重合、溶液重合、乳
化重合および懸濁重合のいずれによっても行える。ＰＶ
ｄＦの製造は、例えば、オートクレーブ中でフロン系溶
媒を分散剤としてＶｄＦモノマーを加圧し、開始剤を添
加して、重合することによって行える。開始剤は例えば
ＩＰＰである。重合は、例えば、６０℃の温度で１０時
間で行える。ＰＶｄＦの量は、通常、組成物の２０〜８
０重量％、好ましくは４０〜６０重量％である。PVdP is a homopolymer of vinylidene fluoride. The molecular weight of PVdF is 10,000-1ooo,oo
It is o. PVdF can be produced by any of bulk polymerization, solution polymerization, emulsion polymerization, and suspension polymerization. PV
dF can be produced, for example, by pressurizing VdF monomer in an autoclave using a fluorocarbon solvent as a dispersant, adding an initiator, and polymerizing. The initiator is, for example, IPP. Polymerization can be carried out, for example, at a temperature of 60° C. for 10 hours. The amount of PVdF typically ranges from 20 to 8% of the composition.
0% by weight, preferably 40-60% by weight.
ＰＭＭＡとＰＶｄＦの相溶体は、例えば、双方のペレッ
トを２００℃以上の溶融状態で混練りすることによって
得られる。その他、ラテックスブレンドや、一方の樹脂
に他方のモノマーを膨潤または溶解させた後、重合させ
て相溶化するなどの種々の方法がある。A compatible solution of PMMA and PVdF can be obtained, for example, by kneading pellets of both in a molten state at 200° C. or higher. In addition, there are various methods such as latex blending and making one resin swell or dissolve the other monomer and then polymerizing it to make it compatible.
本発明の人工水晶体は、白内障手術後の無水晶体眼に対
して人工水晶体として用いることができる。本発明の人
工水晶体は、支持部光学部一体型の１ピースレンズとし
ての使用が望ましい。The artificial lens of the present invention can be used as an artificial lens for an aphakic eye after cataract surgery. The artificial crystalline lens of the present invention is preferably used as a one-piece lens with an integrated supporting part and optical part.
［発明の好ましい態様コ
以下、実施例および比較例を示し、本発明を具体的に説
明する。[Preferred Embodiments of the Invention] The present invention will be specifically explained below with reference to Examples and Comparative Examples.
実施例Ｉ
ＰＭＭＡ（キノダ試薬製試薬ベレット、分子量２００．
０００）５０重量部とＰＶｄＦ（ダイキン工業製ＶＰ−
８２５、分子量１５０，０００）５０重量部とを、樹脂
混合用ニーダ−で２００°Ｃにおいて１０分間混合した
。ポリマーの相溶化は、ＤＳＣにより５６℃にＴｇの単
一ピークが観測されることにより確認した。この相溶体
をヒートブレスにてフィルム（厚さ： ０ 、５ ｍｍ
）に成形した。０．５＋ｎｍ厚のフィルムの透過率は波
長３００〜８００ｎｍで９０％以上であった。このフィ
ルムについてレオメトリックス社製Ｒ５Ａ２で弾性率を
測定した。Example I PMMA (reagent pellet manufactured by Kinoda Reagents, molecular weight 200.
000) 50 parts by weight and PVdF (Daikin Industries VP-
825, molecular weight 150,000) were mixed for 10 minutes at 200°C in a resin mixing kneader. Compatibilization of the polymer was confirmed by observing a single peak of Tg at 56° C. by DSC. This compatible solution was made into a film (thickness: 0, 5 mm) using a heat press.
). The transmittance of the 0.5+nm thick film was greater than 90% at wavelengths from 300 to 800 nm. The elastic modulus of this film was measured using R5A2 manufactured by Rheometrics.
フィルムの弾性率は、室温（２０℃）で１．５ＸＩＯ”
ｄｙｎｅ／ ｃｍ”、４０℃で６ Ｘ １０ ＠ｄｙ
ｎｅ／ ｃｍ’であった。また、切欠きをもっ１／２ｘ
ｌ／２”棒でアイゾツト衝撃試験を行ったところ、衝撃
強さは２０〜２１ｋｇ−ｃｍ／ｃＩ１１であった。この
フィルムが耐衝撃性に優れていることが分かる。The elastic modulus of the film is 1.5XIO" at room temperature (20℃)
dyne/cm”, 6 x 10 @dy at 40°C
It was ne/cm'. Also, add a notch to 1/2x
When an Izot impact test was performed using a 1/2" bar, the impact strength was 20-21 kg-cm/cI11. It can be seen that this film has excellent impact resistance.
比較例１・
実施例１と同様にしてＰＭＭＡ単独のフィルムを作製し
た。粘弾性を測定したところフィルムの弾性率は、２０
℃から４０℃において２Ｘ１０１０ｄｙｎｅ／ｃｍ”で
あり、フィルムはもろかった。また、実施例Ｉと同様に
アイゾツト衝撃試験を行ったところ、衝撃強さは、１．
８ 〜２．２ｋｇ−ｃｍ／ｃｍであった。Comparative Example 1 A film made of PMMA alone was produced in the same manner as in Example 1. When the viscoelasticity was measured, the elastic modulus of the film was 20
℃ to 40℃, and the film was brittle. Also, when an Izot impact test was conducted in the same manner as in Example I, the impact strength was 1.
It was 8 to 2.2 kg-cm/cm.
実施例２
実施例１で得られたフィルムを１ｃｍｘ１ｃｍの正方形
に切り、フィルム試料を作成した。このフィルム試料を
牛血清由来アルブミン（ＢＳＡ）のリン酸緩衝生理食塩
水（ＰＢＳ）０．１％溶液中、３７℃で３０分間、５０
ｍＱのサンプルびん中でスターラーで撹拌し、蛋白を吸
着させた。、ＰＢＳ中で洗浄後、ＢＣＡ蛋白測定キット
（ピアス社製）を用いて付着蛋白を定量したところ０．
３０２±０．０１０μｓ／ａｍ’（ｎ ＝ １０）であ
った。蛋白の付着が少なく、生体成分に対する防汚性に
優れていることがわかる。Example 2 The film obtained in Example 1 was cut into squares of 1 cm x 1 cm to prepare film samples. This film sample was placed in a 0.1% solution of bovine serum-derived albumin (BSA) in phosphate buffered saline (PBS) for 30 minutes at 37°C.
The mixture was stirred with a stirrer in an mQ sample bottle to adsorb protein. After washing in PBS, the attached protein was quantified using a BCA protein measurement kit (manufactured by Pierce) and found to be 0.
It was 302 ± 0.010 μs/am' (n = 10). It can be seen that there is little protein adhesion and excellent stain resistance against biological components.
比較例２
実施例２と同様にＰＭＭＡフィルム試料への蛋白の付着
を定量したところ、０．３７０±０．００５ μｇ／ｃ
ｍ”（ｎ ＝ １０）であった。Comparative Example 2 Protein adhesion to the PMMA film sample was quantified in the same manner as in Example 2, and it was found to be 0.370±0.005 μg/c.
m” (n = 10).
実施例３
実施例１で得られたフィルムについて、薬発令第４８９
号、眼内レンズ承認基準の７．生物学的試験の（３）培
養細胞の増殖阻害試験法に従って、細胞増殖阻害率を測
定した。増殖阻害率は２％以下で、基準値の２９％未満
を大幅に下回った。このことにより、このポリマー相溶
体の安全性が確認できる。Example 3 Regarding the film obtained in Example 1, drug notification No. 489
No. 7 of the intraocular lens approval criteria. The cell growth inhibition rate was measured according to (3) Cultured cell growth inhibition test method in Biological Tests. The growth inhibition rate was less than 2%, which was significantly lower than the standard value of less than 29%. This confirms the safety of this polymer compatible solution.
［発明の効果コ
本発明の人工水晶体において、弾性率は低く、衝撃強さ
もＰＭＭＡに比較して向上しており、１ピ一ス型水晶体
の支持部の破損が生じにくい。また、本発明の人工水晶
体は、細胞増殖阻害試験による毒性がなく、生体内安定
性、防汚性に優れている。[Effects of the Invention] The artificial crystalline lens of the present invention has a low elastic modulus and improved impact strength compared to PMMA, and the supporting portion of the one-piece type crystalline lens is less likely to be damaged. Furthermore, the artificial crystalline lens of the present invention has no toxicity in cell proliferation inhibition tests and has excellent in vivo stability and antifouling properties.
特許出願人ダイキン工業株式会社Patent applicant Daikin Industries, Ltd.
Claims (1)
ライドの相溶体から成る人工水晶体用組成物。 ２、請求項１記載の人工水晶体用組成物から成る人工水
晶体。[Claims] 1. A composition for an artificial lens comprising a compatible solution of polymethyl methacrylate and polyvinylidene fluoride. 2. An artificial crystalline lens comprising the composition for an artificial crystalline lens according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2258098A JPH04135566A (en) | 1990-09-26 | 1990-09-26 | Composition for artificial crystalline lens and artificial crystalline lens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2258098A JPH04135566A (en) | 1990-09-26 | 1990-09-26 | Composition for artificial crystalline lens and artificial crystalline lens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04135566A true JPH04135566A (en) | 1992-05-11 |
Family
ID=17315484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2258098A Pending JPH04135566A (en) | 1990-09-26 | 1990-09-26 | Composition for artificial crystalline lens and artificial crystalline lens |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04135566A (en) |
-
1990
- 1990-09-26 JP JP2258098A patent/JPH04135566A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1177227B1 (en) | Water plasticized high refractive index polymer for ophthalmic applications | |
| EP0777503B1 (en) | Radiopaque polymers and methods for preparation thereof | |
| CN107429024B (en) | Polymer mixture based on fluoropolymer, polymer film, and polarizer protective film | |
| EP1891466B1 (en) | Ophthalmic and otorhinolaryngological device materials | |
| JPH08503506A (en) | Polymer composition and intraocular lens made therefrom | |
| JP2002528043A (en) | Optically transparent ultraviolet absorbing biocompatible polymer material based on collagen and method for producing the same | |
| JP2013529505A (en) | Low refractive ophthalmic acrylic device materials with high refractive index | |
| TW200916130A (en) | Ophthalmic and otorhinolaryngological device materials containing an alkylphenol ethoxylate | |
| TW200816966A (en) | Low-tack ophthalmic and otorhinolaryngological device materials | |
| AU2018279271B2 (en) | High refractive index, high Abbe number intraocular lens materials | |
| JPS6072959A (en) | Polymer blend with high water absorbability | |
| Luo et al. | Novel THTPBA/PEG‐derived highly branched polyurethane scaffolds with improved mechanical property and biocompatibility | |
| Bader | Synthesis and viscoelastic characterization of novel hydrogels generated via photopolymerization of 1, 2-epoxy-5-hexene modified poly (vinyl alcohol) for use in tissue replacement | |
| EP2941445B1 (en) | Flexible, high refractive index hydrophobic copolymer | |
| JPH04135566A (en) | Composition for artificial crystalline lens and artificial crystalline lens | |
| US7354980B1 (en) | High refractive index polymers for ophthalmic applications | |
| JP5732462B2 (en) | Ophthalmic and ENT equipment materials | |
| TW202231746A (en) | Optical films based on styrenic fluoropolymer and acrylic copolymer | |
| Shaik et al. | Interpenetrating photopolymers for intraocular lens application | |
| JPH10152533A (en) | Hydrophilic resin and medical material | |
| JP5504758B2 (en) | Prepolymer | |
| JP3808968B2 (en) | Method for producing blood compatible porous membrane | |
| JP3561740B2 (en) | Biocompatible, optically transparent collagen-based polymer material and method for producing the same | |
| JP2002030117A (en) | Copolymer, crosslinked polymer, contact lens material, contact lens, and method for producing contact lens | |
| JP7246248B2 (en) | Antithrombotic material and method of using antithrombotic material |